{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:06:19Z","timestamp":1790823979347,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.beem.2021.101577","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T11:13:22Z","timestamp":1631272402000},"page":"101577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Menopausal hormone therapy and breast cancer risk"],"prefix":"10.1016","volume":"35","author":[{"given":"Serge","family":"Rozenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Di Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Vandromme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2021.101577_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2013.17","article-title":"Postmenopausal hormone therapy: risks and benefits","volume":"9","author":"Rozenberg","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2021.101577_bib2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE Guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.beem.2021.101577_bib3","doi-asserted-by":"crossref","first-page":"hox007","DOI":"10.1093\/hropen\/hox007","article-title":"HRT for women with premature ovarian insufficiency: a comprehensive review","volume":"2017","author":"Webber","year":"2017","journal-title":"Hum Reprod Open"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09637480701690543","article-title":"Breast density in women with premature ovarian failure using hormone therapy","volume":"24","author":"Benetti-Pinto","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.beem.2021.101577_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/S1516-31802010000400007","article-title":"Breast density in women with premature ovarian failure or postmenopausal women using hormone therapy: analytical cross-sectional study","volume":"128","author":"Soares","year":"2010","journal-title":"Sao Paulo Med J"},{"issue":"9","key":"10.1016\/j.beem.2021.101577_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/GME.0000000000000204","article-title":"Mammographic breast density in women with premature ovarian failure: a prospective analysis","volume":"21","author":"Benetti-Pinto","year":"2014","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.beem.2021.101577_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/13697137.2017.1310836","article-title":"Determinants of percent mammographic density in women with premature ovarian insufficiency","volume":"20","author":"Torelli","year":"2017","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.beem.2021.101577_bib8","article-title":"Impact of premature ovarian failure on mortality and morbidity among Chinese women","volume":"9","author":"Wu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2021.101577_bib9","series-title":"Hormone therapy in primary ovarian insufficiency","first-page":"e134","volume":"129","year":"2017"},{"issue":"31","key":"10.1016\/j.beem.2021.101577_bib10","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beem.2021.101577_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/GME.0000000000000325","article-title":"Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency","volume":"22","author":"Rah","year":"2015","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2010.04.011","article-title":"EMAS position statement: managing women with premature ovarian failure","volume":"67","author":"Vujovic","year":"2010","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.beem.2021.101577_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/13697137.2020.1804547","article-title":"Premature ovarian insufficiency: an international menopause society white paper","volume":"23","author":"Panay","year":"2020","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.beem.2021.101577_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(08)70033-0","article-title":"Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study","volume":"9","author":"Schoemaker","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/EJE-20-0702","article-title":"Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy","volume":"184","author":"Viuff","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"24","key":"10.1016\/j.beem.2021.101577_bib16","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMc062795","article-title":"Hormone replacement and the risk of breast cancer in Turner's syndrome","volume":"355","author":"B\u00f6sze","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.beem.2021.101577_bib17","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2017-02183","article-title":"Estrogen replacement in turner syndrome: literature review and practical considerations","volume":"103","author":"Klein","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2021.101577_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"Verkerk","year":"1991","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.beem.2021.101577_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102370","article-title":"Absence of BRCA\/FMR1 correlations in women with ovarian cancers","volume":"9","author":"Gleicher","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2021.101577_bib20","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1017\/S0016672314000147","article-title":"FMR1 CGG allele length in Israeli BRCA1\/BRCA2 mutation carriers and the general population display distinct distribution patterns","volume":"96","author":"Laitman","year":"2014","journal-title":"Genet Res"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.beem.2021.101577_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","article-title":"Hormone replacement therapy in cancer survivors - review of the literature","volume":"26","author":"Deli","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"10.1016\/j.beem.2021.101577_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.beem.2021.101577_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10689-008-9208-6","article-title":"Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy","volume":"8","author":"Gabriel","year":"2009","journal-title":"Fam Cancer"},{"issue":"8","key":"10.1016\/j.beem.2021.101577_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hereditary breast cancer clinical study group. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.beem.2021.101577_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.beem.2021.101577_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Canc Res Treat"},{"issue":"6","key":"10.1016\/j.beem.2021.101577_bib29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2004.06.090","article-title":"Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1\/2 mutations: a decision analysis","volume":"22","author":"Armstrong","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beem.2021.101577_bib30","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr3405","article-title":"Risk of breast cancer in Lynch syndrome: a systematic review","volume":"15","author":"Win","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.beem.2021.101577_bib31","series-title":"Uptofate Literature review current through","article-title":"Factors that modify breast cancer risk in women","year":"2021"},{"issue":"6","key":"10.1016\/j.beem.2021.101577_bib32","doi-asserted-by":"crossref","first-page":"dgaa073","DOI":"10.1210\/clinem\/dgaa073","article-title":"Underlying breast cancer risk and menopausal hormone therapy","volume":"105","author":"Santen","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2021.101577_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.beem.2021.101577_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/13697137.2018.1476483","article-title":"Progesterone, progestins and the breast in menopause treatment","volume":"21","author":"Gompel","year":"2018","journal-title":"Climacteric"},{"issue":"7","key":"10.1016\/j.beem.2021.101577_bib35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2021.101577_bib36","first-page":"CD008536","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.beem.2021.101577_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13697137.2019.1568403","article-title":"Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators","volume":"22","author":"Pinkerton","year":"2019","journal-title":"Climacteric"},{"issue":"9","key":"10.1016\/j.beem.2021.101577_bib38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1514242","article-title":"Menopause management--getting clinical care back on track","volume":"374","author":"Manson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.beem.2021.101577_bib39","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/GME.0000000000001241","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"25","year":"2018","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.beem.2021.101577_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehaa1044","article-title":"Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists","volume":"42","author":"Maas","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.beem.2021.101577_bib41","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00198-020-05497-8","article-title":"Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?","volume":"31","author":"Rozenberg","year":"2020","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.beem.2021.101577_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:57:41Z","timestamp":1761497861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X21000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521690X21000944"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2021.101577","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopausal hormone therapy and breast cancer risk","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2021.101577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101577"}}